Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>SH-4-54

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

SH-4-54

CAS NO.1456632-40-8

  • Min.Order: 0 Metric Ton
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • SH-4-54
  • best price
  • high purity

Quick Details

  • ProName: SH-4-54
  • CasNo: 1456632-40-8
  • Molecular Formula: C29H27F5N2O5S
  • Appearance: white powder
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 10 Milligram /Day
  • Purity: ≥98%
  • Storage: room temperature
  • Transportation: by air
  • LimitNum: 0 Metric Ton

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

SH-4-54 is a most potent, small molecule, nonphosphorylated STAT3 inhibitor, strongly binds to STAT3 protein (KD = 300 nM), is selective for STAT3 over STAT1. IC50 value: 300 nM (KD, for STAT3) Target: STAT3 in vitro: SH-4-54 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations.SH-4-54 shows unprecedented cytotoxicity in human BTSCs, displayed no toxicity in human fetal astrocytes, potently suppressed pSTAT3 with nanomolar IC50s, inhibited STAT3's downstream targets, and showed no discernible off-target effects at therapeutic doses. in vivo: SH-4-54 exhibits blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo. SH-4-54 demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.SH-4-54 decreases pSTAT3 expression in tumor cells of treated mice. SH-4-54 appears to decrease proliferation and increase apoptosis of treated tumors.

Hot Product